Mike Abbadessa, VP SME head of Medical Affairs at Within3, explores the benefits of pharma going virtual and whether the industry is prepared to do so.
For pharma companies, predicting where the sector will evolve is key to business planning. By staying ahead of the curve, companies can best position themselves to get results. While the unpredictable events of both 2020 and 2021 threw the pharma sector off track, the industry proactively adapted to the situation.
In 2021, we saw decentralised trials come to the forefront, along with an acceleration of virtual care by the wider healthcare sector. Many were predicting virtual engagement to be the trend for the next five, 10, 15 years, but its adoption has taken just two. So, what follows this? How does virtual engagement continue to move at pace throughout the pharma industry to drive results, gain insights and equip teams for a post-covid pharma sector?